Search
Menu
Home
HTB
2016
July
July 2016
Contents
Special reports
HTB supplement: 2016 Pipeline Report
Pipeline report
Acknowledgments
Dedications
Executive summary – HIV
Executive summary – tuberculosis
The antiretroviral pipeline 2016
Fit for purpose: antiretroviral treatment optimisation 2016
The paediatric antiretroviral pipeline
Preventive technologies: antiretroviral and vaccine development
Research toward a cure and immune-based and gene therapies
The tuberculosis diagnostics pipeline
The tuberculosis prevention pipeline
The tuberculosis treatment pipeline: activity, but no answers
The paediatric tuberculosis treatment pipeline: beyond pharmacokinetics and safety data
2016 hepatitis C virus (HCV) update
HTB RSS
Early access
The RIO study: Q&A about controlling HIV with bNAbs
21 April 2025
Lenacapavir EAP in the UK closed to new referrals: NHS England and Gilead fail to agree a price after more than two years
20 April 2025
Viral failure on CAB/RPV-LA: overcoming drug resistance with second-generation INSTIs
13 April 2025
Lancet HIV recognises Transgender Day of Visibility and the importance of gender-affirming hormones in HIV care
3 April 2025
All early access reports
Current issues
April 2025
March 2025
February 2025
Back issues
Special report
Lancet HIV recognises Transgender Day of Visibility and the importance of gender-affirming hormones in HIV care
3 April 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate